Xenetic Biosciences, Inc. — 2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021; filed March 22, 2022. This is an annual report, not a standalone fourth-quarter report. Xenetic is a clinical-stage biopharmaceutical company with no approved products or product sales. Its main internal development focus is XCART, a personalized CAR T platform for B-cell lymphomas; it also earns royalties from its PolyXen technology.
Financial performance and liquidity
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue, all royalty revenue | $1.16 million | $0.44 million |
| Research and development expense | $3.16 million | $1.73 million |
| General and administrative expense | $3.74 million | $3.40 million |
| Operating loss | $5.75 million | $13.94 million |
| Net loss | $5.65 million | $10.89 million |
| Net loss per share, basic and diluted | $0.55 | $1.70 |
| Cash used in operating activities | $4.74 million | $4.27 million |
| Cash at year-end | $18.24 million | $11.53 million |
- Revenue rose 165.6%, driven by higher Takeda sublicense royalties: approximately $1.2 million in 2021 versus $0.4 million in 2020. Royalties are the company’s only reported revenue source.
- R&D increased 82.7%, primarily from greater XCART preclinical spending. Operating and net losses narrowed mainly because 2020 included a $9.24 million impairment charge and a $2.92 million income tax benefit; neither recurred in 2021.
- Working capital was $17.3 million, compared with $11.4 million in 2020. Current liabilities were $1.42 million. The filing reports no outstanding debt liabilities at year-end; it does report a related-party loan receivable.
- Financing activities provided $11.45 million, principally from a July 2021 private placement. No cash flows from investing activities were reported. The filing does not provide a clear gross-margin figure.
Material changes and business developments
- In July 2021, Xenetic completed a private placement with approximately $12.5 million in gross proceeds and $11.5 million in net proceeds. It issued 950,000 common shares and warrants; all 3.68 million pre-funded warrants were exercised during 2021. Series A warrants to buy 4.63 million shares at $3.30 remained outstanding at year-end.
- A November 2021 at-the-market facility permits up to $4 million in common-stock sales; no shares were sold under it during 2021.
- Xenetic and Takeda mutually terminated their exclusive PolyXen research and development agreement in August 2021. The separate sublicense arrangement remained in effect and continued generating royalties.
- The company amended its Pharmsynthez services arrangement in October 2021, ending prior work orders and establishing a new work order for requested XCART support.
- Pharmsynthez had not informed Xenetic that Russian registration or production of ErepoXen/Epolong had been completed or commenced, despite previously reported expectations for 2021 registration activities and production in early 2022.
Outlook, risks and unusual items
- Management expects continuing operating losses and states that the company will need additional capital in the long term. It estimates that year-end cash, together with the 2021 financing, will fund operations into the second quarter of 2023. The filing nevertheless says substantial doubt exists about the company’s ability to continue as a going concern; the auditor identified the going-concern assessment as a critical audit matter.
- No formal financial or product-development guidance is provided. XCART remains in preclinical development, and there is no manufacturing agreement in place for its clinical materials. Development, regulatory approval and commercialization remain uncertain.
- The business depends substantially on XCART’s progress, external collaborators and contractors, future financing, and royalty revenue from a limited source. Clinical, manufacturing, regulatory, intellectual-property, competition, reimbursement and dilution risks are significant.
- Geopolitical developments are relevant: Xenetic has Russian collaborators and a loan receivable from Pharmsynthez. In February 2022, Pharmsynthez requested another extension of principal repayments; Xenetic agreed to extend the maturity, with final terms still under negotiation. The company said the collateral—Pharmsynthez- and SynBio-owned Xenetic shares—was adequate, but classified the receivable as long-term amid Russia-Ukraine-related uncertainty and sanctions.
- Preferred stock carries liquidation preferences and conversion rights that may dilute common holders. The company had approximately 13.44 million common shares outstanding as of March 18, 2022.
- The auditor issued an unqualified opinion on the financial statements. Management reported effective disclosure controls and internal control over financial reporting; the auditor was not engaged to attest to internal-control effectiveness.
Important facts for investors to verify
- Whether XCART achieves development milestones, secures a clinical-supply manufacturer, and advances toward an IND filing.
- Actual cash burn and financing needs relative to management’s stated runway into Q2 2023, including any use of the $4 million ATM facility.
- Takeda royalty trends and the timing and reliability of reported sublicense sales.
- Collection and final repayment terms for the Pharmsynthez loan, and any effects of sanctions or geopolitical disruption on collaboration work.
- Potential dilution from outstanding Series A warrants, preferred stock, equity awards and other securities, and the rights attached to preferred stock.
- Whether ErepoXen receives Russian authorization or enters production; the filing does not confirm either event.